SCTX (Scribe Therapeutics) EV-to-OCF: (As of Sep. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCTX Scribe Therapeutics Inc SCTX
8 GF Score
Price $30.01
! 1 Warning Sign
View Full Analysis

What is Scribe Therapeutics EV-to-OCF?

EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Scribe Therapeutics's Enterprise Value is $568.40 Mil. Scribe Therapeutics does not have enough years/quarters to calculate its Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Scribe Therapeutics's EV-to-OCF at this moment.

The historical rank and industry rank for Scribe Therapeutics's EV-to-OCF or its related term are showing as below:

SCTX' s EV-to-OCF Range Over the Past 10 Years
Min: -12.76   Med: 0   Max: -12.25
Current: -12.57

During the past 2 years, the highest EV-to-OCF of Scribe Therapeutics was -12.25. The lowest was -12.76. And the median was .

SCTX's EV-to-OCF is ranked better than
74.88% of 1405 companies
in the Biotechnology industry
Industry Median: -3.4 vs SCTX: -12.57

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-09-11), Scribe Therapeutics's stock price is $30.01. Scribe Therapeutics does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Scribe Therapeutics's PE Ratio (TTM) at this moment.

Scribe Therapeutics  (NAS:SCTX) EV-to-OCF Explanation

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Scribe Therapeutics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=30.01/
=

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Scribe Therapeutics EV-to-OCF Related Terms

Scribe Therapeutics EV-to-OCF Historical Data

* Premium members only.

The historical data trend for Scribe Therapeutics's EV-to-OCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scribe Therapeutics EV-to-OCF Chart

Scribe Therapeutics Annual Data
Trend Dec24 Dec25
EV-to-OCF
0.00 0.00

Scribe Therapeutics Semi-Annual Data
Dec24 Dec25
EV-to-OCF 0.00 0.00

SCTX vs ARTV, CABA, OVID: EV-to-OCF Comparison

For the Biotechnology subindustry, Scribe Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scribe Therapeutics EV-to-OCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scribe Therapeutics's EV-to-OCF distribution charts can be found below:

* The bar in red indicates where Scribe Therapeutics's EV-to-OCF falls into.


SCTX
8GF Score
Scribe Therapeutics Inc SCTX
EV-to-OCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scribe Therapeutics EV-to-OCF Calculation

Scribe Therapeutics's EV-to-OCF for today is calculated as:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=568.401/
=

Scribe Therapeutics Business Description

Address 1150 Marina Village Parkway, Alameda, CA, USA, 94501
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
8GF Score

Get the complete analysis for SCTX

EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$30.01
Price